Commercializing Continuous Processing in Pharma

Safety, Efficacy, Efficiency and Quality: Scaling Your Continuous Processing from Technology to Commercial Manufacturing

Four years in the drug development world isn’t long, and the progress made in continuous processing has been an extraordinary. Thanks to the encouragement of the FDA and maturing technology; both pharma and biotech are starting to adopt continuous manufacturing (CM) in a commercial setting.

Over the last 12 months we have seen major milestones in continuous manufacturing globally – PROSPECT project in the UK, GSK’s announcement of CM facilities in Singapore, Merck has filed an NDA under CM approach, Bill and Melinda Gates Foundation granted $14.3m to Univercells to deploy CM for measles and rubella vaccine continuous manufacturing.

At the 4th Annual CCP Summit we will continue to explore scientific and technology advancements that can help eliminate bottlenecks, and more importantly, will address the quality, upfront investment and business rationale behind the ‘switch’.

Returning to Boston for the 4th time on Jan 28 – 30, 2020 – Get involved now!

Others Details

Time: 8:00 am to 5:30 pm Speakers: Manuel Osorio, Senior Scientist and Program Lead for Emerging Technologies, FDA/CBER, Ganapathy Mohan, Executive Director, Head of External Affairs (Quality), Merck and Co., Inc., Justin Moser Director – Advanced Manufacturing Technology Merck and Co., Inc. and many more.